Abstract
Because of the difficulties patients have in adhering to their drug regimens a trial was performed in which patients with essential hypertension were given, in random order and for four weeks each, three different doses of atenolol to be taken once daily. Atenolol effectively decreased lying and standing blood pressures, and there was no difference between the effects of the three doses. The simplicity of the regimen, as well as atenolol's freedom from troublesome side effects, should be valuable in helping patients adhere to long-term treatment.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Blackwell B. Drug therapy: patient compliance. N Engl J Med. 1973 Aug 2;289(5):249–252. doi: 10.1056/NEJM197308022890506. [DOI] [PubMed] [Google Scholar]
- Hansson L., Aberg H., Jameson S., Karlberg B., Malmcrona R. Initial clinical experience with I.C.I. 66.082, a new beta-adrenergic blocking agent, in hypertension. Acta Med Scand. 1973 Dec;194(6):549–550. doi: 10.1111/j.0954-6820.1973.tb19489.x. [DOI] [PubMed] [Google Scholar]
- Marlin G. E., Kumana C. R., Kaye C. M., Smith D. M., Turner P. An investigation into the cardiac and pulmonary beta-adrenoceptor blocking activity of ICI 66,082 in man. Br J Clin Pharmacol. 1975 Apr;2(2):151–157. doi: 10.1111/j.1365-2125.1975.tb01570.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Petrie J. C., Galloway D. B., Webster J., Simpson W. T., Lewis J. A. Atenolol and bendrofluazide in hypertension. Br Med J. 1975 Oct 18;4(5989):133–135. doi: 10.1136/bmj.4.5989.133. [DOI] [PMC free article] [PubMed] [Google Scholar]